ReviewInfectious medicine2025
Phage treatment of multidrug-resistant bacterial infections in humans, animals, and plants: The current status and future prospects.
Review in Infectious medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Bacteriophages in Hip and Knee Periprosthetic Joint Infections: A Promising Tool in the Era of Antibiotic Resistance.Medical sciences (Basel, Switzerland) · 2025Pooled it
- Isolation and characterization of two phages infectingThe Journal of general virology · 2026Article
- Systematic combinatorial optimization of three-phage cocktails against multidrug-resistantMicrobiology spectrum · 2026Article
- Molecular Insights into Phage-Hydrogel Polymer Interactions Through Docking, Molecular Dynamics, and Machine Learning.Polymers · 2026Article
- Bacteriophage-Based Control of Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Phage biobanks as enabling infrastructure for precision phage therapy in the era of antimicrobial resistance.Frontiers in antibiotics · 2026Article
- The WHO priority list of antibiotic-resistant bacteria: challenges and opportunities for next-generation antimicrobial development.Frontiers in pharmacology · 2026Review
- Genomic, Functional, and Evolutionary Insights into a Novel T7-like Phage B1 Infecting Multidrug-ResistantInternational journal of molecular sciences · 2025Article
- Neonatal and pediatric sepsis: Microbiological insights, diagnostic innovations, and antimicrobial challenges.World journal of clinical pediatrics · 2025Review
- More Is Not Always Better: Co-Occurrence Analysis of Anti-Phage Systems Reveals Prevalent Neutral Interactions inMicroorganisms · 2025Article
- Isolation and characterization of multi-drug-resistant Microbacterium esteraromaticum bacteriophage: assessment of antibacterial efficacy and genomic insights.International microbiology : the official journal of the Spanish Society for Microbiology · 2025Article
- Engineered Phage-Guided Nanotherapeutic Systems for Precision Antibacterial Therapy: Hacking Bacterial Resistance Mechanisms.Pharmaceutics · 2025Review
- Is a Bacteriophage Approach for Musculoskeletal Infection Management an Alternative to Conventional Therapy?Life (Basel, Switzerland) · 2025Article
- Role of the Virome in Vaccine-Induced Immunization.Vaccines · 2025Review
- Latest Advances in Inhalable Dry Powder Bacteriophage Therapy for Pulmonary Infections.Pharmaceutics · 2025Review
- Genomic analysis of five new mycobacteriophages belonging to the F, G, K, and P clusters.3 Biotech · 2025Article
- Phage Therapy in Managing Multidrug-Resistant (MDR) Infections in Cancer Therapy: Innovations, Complications, and Future Directions.Pharmaceutics · 2025Review
- Harnessing phages to tackle antimicrobial resistance: a Saudi Arabian perspective.Frontiers in cellular and infection microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phages, including the viruses that lyse bacterial pathogens, offer unique therapeutic advantages, including their capacity to lyse antibiotic-resistant bacteria and disrupt biofilms without harming the host microbiota. The lack of new effective antibiotics and the growing limitations of existing antibiotics have refocused attention on phage therapy as an option in complex clinical cases such as burn wounds, cystic fibrosis, and pneumonia. This review describes clinical cases and preclinical studies in which phage therapy has been effective in both human and veterinary medicine, and in an agricultural context. In addition, critical challenges, such as the narrow host range of bacteriophages, the possibility of bacterial resistance, and regulatory constraints on the widespread use of phage therapy, are addressed. Future directions include optimizing phage therapy through strategies ranging from phage cocktails to broadening phage host range through genetic modification, and using phages as vaccines or biocontrol agents. In the future, if phage can be efficiently delivered, maintained in a stable state, and phage-antibiotic synergy can be achieved, phage therapy will offer much needed treatment options. However, the successful implementation of phage therapy within the current standards of practice will also require the considerable development of regulatory infrastructure and greater public acceptance. In closing, this review highlights the promise of phage therapy as a critical backup or substitute for antibiotics. It proposes a new role as a significant adjunct to, or even replacement for, antibiotics in treating multidrug-resistant bacterial infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.